Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Now Covered by Analysts at Evercore

Evercore began coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a report issued on Wednesday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $46.00 price objective on the stock.

DMRA has been the topic of several other research reports. Lifesci Capital raised shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, February 2nd. Wall Street Zen upgraded shares of Damora Therapeutics, Inc. Common Stock from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Guggenheim restated a “buy” rating and set a $40.00 target price (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Zacks Research raised shares of Damora Therapeutics, Inc. Common Stock to a “hold” rating in a report on Friday, January 9th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $44.25.

Damora Therapeutics, Inc. Common Stock Stock Up 4.7%

DMRA stock opened at $25.05 on Wednesday. The business’s 50-day moving average price is $26.97 and its 200-day moving average price is $19.45. The stock has a market cap of $1.51 billion, a P/E ratio of -2.07 and a beta of 1.42. Damora Therapeutics, Inc. Common Stock has a twelve month low of $2.01 and a twelve month high of $38.33.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Several institutional investors and hedge funds have recently modified their holdings of DMRA. Ikarian Capital LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $6,574,000. Janus Henderson Group PLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $40,000. Boothbay Fund Management LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $2,204,000. Jain Global LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $2,774,000. Finally, Remedium Capital Partners LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $2,772,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.